Keyword: Department of Health and Human Services (HHS)
For pharmas, the directive could mean disclosing information on drug prices and those behind-the-scenes discounts and rebates they pay PBMs.
Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.
Officials from both parties have come up with a possible alternative to HHS' rebate-nixing idea: an out-of-pocket cap in Medicare Part D.
It’s official. HHS will require pharma companies to include list prices in TV ads—and the industry will have just over two months to do it.
After Mylan's high-profile EpiPen misclassification, lawmakers have passed a bill cracking down on Medicaid misrepresentations that cost taxpayers.
Johnson & Johnson’s anticoagulant Xarelto has picked up an industry first.
Eli Lilly reports that Humalog's net prices have slipped by 8% in recent years even as the company raised list prices 52%.
Measures in Trump's 2020 budget aim to incentivize lower list prices, promote competition and more.
UnitedHealthcare is making demands about pharma's new strategy to lower prices, an analyst wrote.
Top PBM Express Scripts said that its efforts saved clients $45 billion in 2018, and its clients' drug costs grew just 0.4% last year.